Pear Therapeutics announced today that MassHealth intends to cover the company’s prescription digital therapeutics (PDTs).
MassHealth, Massachusetts’ Medicaid program, notified Pear of its plans to cover the FDA-authorized reSET and reSET-O PDTs for treating substance use disorder and opioid use disorder, respectively. The decision remains subject to certain customary conditions, including federal and state approvals as well as sufficient funding on both levels.
